While CFTR modulators decreased the inflammatory response (Hisert et al., 2017; Zhang et al., 2018; Jarosz-Griffiths et al., 2020), and improved their bacterial clearance (Barnaby et al., 2018; Zhang et al., 2018) in monocyte/MΦs from patients with CF, these studies did not investigate a possible increase (and thus beneficial effect) of HO-1 levels. The gene discussed is HMOX1; the disease is cystic fibrosis.